The Evolving Frontier of Immune Checkpoint Blockade in Type 1 Diabetes

Type 1 diabetes (T1D) remains one of the most challenging autoimmune disorders, characterized by the progressive destruction of insulin-producing beta cells in the pancreatic islets by autoreactive T cells. While exogenous insulin therapy has been the standard of care for decades, it does not address the underlying immune pathology. Recent breakthroughs in cancer immunotherapy—specifically immune checkpoint blockade—have sparked a paradigm shift in how researchers approach autoimmune diseases like T1D. By modulating the same molecular pathways that tumors exploit to evade immune surveillance, scientists are now exploring whether checkpoint-based strategies can restore immune tolerance and preserve residual beta cell function. This article provides a comprehensive overview of the latest developments in immune checkpoint blockade for T1D, covering mechanistic insights, preclinical advances, emerging clinical trials, and the hurdles that remain before these therapies can reach the clinic.

The Immune Checkpoint Landscape in Autoimmunity

Immune checkpoints are a diverse family of receptors and ligands that serve as critical regulators of T cell activation, proliferation, and effector function. Under normal physiological conditions, they prevent overactive immune responses that could damage healthy tissues. In T1D, the delicate balance between co-stimulatory and co-inhibitory signals is disrupted. Autoreactive CD4+ and CD8+ T cells escape central and peripheral tolerance mechanisms and mount a sustained attack against beta cell antigens such as insulin, GAD65, IA-2, and ZnT8. Key checkpoints that have been implicated in T1D pathogenesis include programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), lymphocyte activation gene 3 (LAG-3), and T cell immunoglobulin and mucin-domain containing-3 (TIM-3). Understanding how these molecules are expressed and function in the autoimmune milieu is essential for designing targeted interventions.

PD-1, for instance, is an inhibitory receptor expressed on activated T cells, and its ligands PD-L1 and PD-L2 are found on antigen-presenting cells, pancreatic islet cells, and various tissues. In healthy individuals, the PD-1/PD-L1 axis promotes peripheral tolerance and limits tissue damage during inflammation. However, in T1D, reduced PD-1 signaling on autoreactive T cells has been observed, correlating with disease progression. Similarly, CTLA-4 competes with the co-stimulatory receptor CD28 for binding to CD80/CD86 on antigen-presenting cells, thereby dampening T cell responses. Genetic polymorphisms in CTLA-4 have been linked to T1D susceptibility, underscoring its relevance. These checkpoints offer promising druggable targets for re-establishing immune homeostasis.

Recent Advances in Checkpoint Modulation for T1D

PD-1 Agonism: Turning the Immune Brake Back On

Unlike cancer therapy, where checkpoint inhibitors (e.g., anti-PD-1, anti-CTLA-4) are used to unleash antitumor immunity, autoimmune diseases like T1D require the opposite—checkpoint agonism to suppress pathological immune activity. Recent preclinical work has focused on developing PD-1 agonists that mimic the natural inhibitory signal. For example, a PD-1-Fc fusion protein (a soluble recombinant form of PD-1) has been tested in non-obese diabetic (NOD) mice, the gold-standard animal model for T1D. Treatment with this agent reduced insulitis, preserved beta cell mass, and improved glucose tolerance. Similarly, agonistic antibodies targeting PD-1 have been engineered that crosslink the receptor and trigger downstream inhibitory signaling pathways. These approaches aim to selectively dampen autoreactive T cells without causing global immunosuppression.

A particularly promising strategy involves bispecific molecules that simultaneously engage PD-1 and another inhibitory receptor, such as CTLA-4 or LAG-3, to achieve synergistic suppression. Early data from NOD mouse studies indicate that such dual-targeting agents can more effectively halt autoimmune insulitis and even reverse recent-onset hyperglycemia. These findings have laid the groundwork for translating PD-1 agonism into human clinical trials, though challenges remain regarding pharmacokinetics, tissue penetration, and the risk of impairing protective immunity against infections.

CTLA-4 Ig (Abatacept) in T1D: Clinical Insights

While CTLA-4 is a classic checkpoint, its therapeutic modulation in T1D has advanced furthest through the use of the fusion protein abatacept (CTLA-4 Ig). Abatacept mimics the inhibitory function of CTLA-4 by binding to CD80/CD86 and blocking CD28-mediated co-stimulation. The landmark TrialNet study (NCT00505375) randomized recent-onset T1D patients (aged 6–45 years) to receive abatacept or placebo over a two-year period. Results showed that abatacept significantly slowed the decline in beta cell function (measured by C-peptide area under the curve) compared to placebo, and the effect persisted for at least one year after treatment cessation. However, the benefit waned over time, suggesting that repeated or longer dosing may be needed.

More recent analysis of abatacept-treated patients revealed that responders had a distinct baseline immunophenotype, including lower frequencies of CD8+ effector memory T cells and higher expression of genes related to immune regulation. This highlights the potential for precision medicine approaches to select patients most likely to benefit. Ongoing trials are now exploring abatacept in combination with other agents, such as rituximab (anti-CD20) or tocilizumab (anti-IL-6R), to achieve a more durable impact on beta cell preservation.

LAG-3 and TIM-3: Emerging Targets

Beyond PD-1 and CTLA-4, several other checkpoints are gaining attention in T1D research. LAG-3 is an inhibitory receptor that binds to MHC class II molecules with high affinity and is often co-expressed with PD-1 on exhausted T cells. In the NOD mouse model, blocking LAG-3 alone modestly accelerated diabetes, while combined blockade of LAG-3 and PD-1 led to rapid disease onset, indicating that these pathways synergistically maintain tolerance. Conversely, LAG-3 agonists are being developed to enhance suppression. A soluble LAG-3-Ig fusion protein has shown efficacy in reducing T cell proliferation and cytokine production in vitro, and early in vivo studies are underway.

TIM-3 is another checkpoint receptor expressed on Th1 and CD8+ T cells, and its ligand galectin-9 is abundant in pancreatic islets. TIM-3 engagement promotes T cell apoptosis and exhaustion, and its expression is reduced on beta-cell-autoreactive T cells in T1D patients. Agonistic anti-TIM-3 antibodies have been shown to reverse diabetes in NOD mice when administered early after disease onset, likely by expanding regulatory T cell (Treg) populations and promoting a tolerogenic cytokine milieu. These preclinical successes underscore the therapeutic potential of targeting multiple checkpoints in a coordinated fashion.

Emerging Therapies and Clinical Trial Landscape

Teplizumab and the Checkpoint Connection

While teplizumab (an Fc-engineered anti-CD3 monoclonal antibody) is not a checkpoint modulator per se, its mechanism involves partial T cell depletion and induction of Tregs, which indirectly enhances inhibitory checkpoint signaling. In 2022, teplizumab became the first drug approved by the FDA to delay the onset of stage 3 T1D in at-risk individuals (stage 2). Notably, teplizumab-treated patients showed increased expression of PD-1 on CD8+ T cells and a shift toward a less differentiated T cell phenotype. This suggests that checkpoint modulation may be an integral part of teplizumab’s efficacy, opening the door for combining anti-CD3 with direct checkpoint agonists to improve outcomes.

Checkpoint Agonists in Early-Phase Clinical Trials

Several biotech companies have advanced checkpoint agonists into phase 1/2 trials for autoimmune indications, including T1D. For instance, a PD-L1-Fc fusion protein (designed to activate PD-1 signaling) is being evaluated in a multicenter trial for recent-onset T1D (NCT04522575). Preliminary safety data from the first cohorts indicate acceptable tolerability, with no severe immune-related adverse events reported, although efficacy endpoints (C-peptide preservation) are pending. Another trial is testing a bispecific antibody that co-targets PD-1 and CTLA-4 (NCT04913675) in patients with established T1D to assess safety, pharmacokinetics, and immunomodulatory effects.

In addition, a novel approach using engineered exosomes displaying PD-L1 on their surface has shown promise in NOD mice by delivering checkpoint signals directly to the pancreatic lymph nodes. A phase 1 trial of this exosomal therapy is expected to launch in 2025, which could represent a paradigm shift in targeted immunotherapy delivery. Meanwhile, researchers are also exploring viral vector-based gene therapy to express checkpoint ligands locally in the pancreas, thereby avoiding systemic immunosuppression. Preclinical data using adeno-associated virus (AAV) vectors encoding PD-L1 under a beta-cell-specific promoter have demonstrated reduced insulitis and maintained glucose control in diabetic mice.

Combination Strategies: Targeting Multiple Arms of the Immune Response

Given the multifactorial nature of T1D, monotherapies are unlikely to induce long-term tolerance. Combination regimens that simultaneously block multiple autoimmune pathways—while augmenting regulatory mechanisms—are actively being tested in preclinical models and early clinical settings. Examples include:

  • PD-1 agonist + low-dose IL-2 to expand Tregs while suppressing effector T cells. IL-2 at low doses preferentially binds to high-affinity IL-2 receptors on Tregs, promoting their survival and suppressive activity.
  • CTLA-4 Ig (abatacept) + anti-CD20 (rituximab) to deplete B cells and block co-stimulation. A pilot study in recent-onset T1D showed a synergistic effect on preserved C-peptide at 12 months compared to either agent alone.
  • Checkpoint agonist + antigen-specific therapy, such as administering GAD-alum with a PD-1 agonist to selectively tolerize autoreactive T cells while leaving the rest of the immune system intact.
  • Checkpoint modulation combined with beta cell regeneration, using agents like GLP-1 receptor agonists or stem cell-derived islets to restore insulin production once the immune attack is silenced.

Early data from these combination trials are encouraging, but the complexity of dosing schedules, potential for overlapping toxicities, and high cost of development remain significant barriers.

Challenges and Hurdles on the Path to Clinical Adoption

One of the foremost concerns with checkpoint agonists is the risk of unintended global immunosuppression, which could increase susceptibility to infections and impair tumor surveillance. While cancer checkpoint inhibitors have well-characterized immune-related adverse events (irAEs) such as colitis, pneumonitis, and endocrinopathies, the opposite approach—activation of inhibitory checkpoints—may also cause side effects. For example, chronic PD-1 agonism might dampen immune responses against common pathogens or reactivate latent viruses like cytomegalovirus (CMV) or Epstein-Barr virus (EBV). Clinical trials to date have reported mild-to-moderate infection rates, but long-term follow-up is lacking. Additionally, because T1D patients are often young and otherwise healthy, the risk-benefit calculus must be carefully considered.

Another safety concern is the potential for checkpoint agonists to paradoxically enhance autoimmune responses in certain contexts. For instance, some PD-1 agonists have been shown to activate regulatory mechanisms that inadvertently promote Th17 responses or antibody production in animal models, leading to worsened disease. These findings highlight the need for careful biomarker monitoring and adaptive trial designs.

Identifying the Optimal Therapeutic Window

Timing of intervention is critical in T1D. The disease progresses through distinct stages: stage 1 (normoglycemia with two or more autoantibodies), stage 2 (dysglycemia with autoantibodies), and stage 3 (clinical onset with hyperglycemia). Checkpoint agonists are likely to be most effective when initiated early, before substantial beta cell loss has occurred. However, identifying individuals at high risk for progression remains challenging. Widespread autoantibody screening, as implemented by programs like TrialNet and INNODIA, is increasing the pool of eligible participants, but many at-risk individuals never progress to clinical disease. Over-treating these individuals with immunomodulatory agents could expose them to unnecessary risks. Therefore, refined risk stratification using genetic scores, metabolomics, and T cell assays is essential.

Furthermore, the dose and duration of checkpoint agonist therapy must be optimized. Too short a course may only provide transient benefit, while continuous therapy raises concerns about long-term safety and cost. Some studies are exploring intermittent dosing strategies that synchronize with periods of high autoimmune activity, such as after infections or metabolic stress.

Individual Variability in Immune Responses

Immune profiles vary widely among T1D patients, influenced by age, gender, HLA genotype, gut microbiome composition, and environmental exposures. For example, patients with a higher frequency of exhausted PD-1+ CD8+ T cells may respond differently to PD-1 agonists compared to those with predominantly naive autoreactive T cells. Biomarker-driven patient selection is already being tested in ongoing trials, but the discovery and validation of reliable predictive biomarkers—such as soluble checkpoint levels, T cell receptor repertoire diversity, or epigenetic signatures—remain a top priority. Without such tools, checkpoint agonist therapy may appear ineffective in unselected populations, dampening enthusiasm for further development.

Future Directions and Unanswered Questions

Personalized Immunotherapy: A Path Forward

The ultimate goal in T1D immunotherapy is to achieve durable immune tolerance without lifelong drug dependence. Personalized approaches that combine checkpoint agonism with other modalities—such as autologous Treg cell therapy, antigen-specific nanoparticles, or CRISPR-edited hematopoietic stem cells—hold great promise. For instance, engineered Tregs that overexpress PD-1 and recognize beta cell antigens could home to the pancreas and locally suppress autoreactive effectors. Phase 1 trials of polyclonal Treg infusion have shown safety and some signs of efficacy, and adding checkpoint genetic modifications may enhance their potency.

Another frontier is the use of microbiome modulation to influence checkpoint expression. The gut microbiome regulates systemic immune tone, and specific bacterial species have been associated with reduced PD-1 expression on T cells in T1D. Preclinical studies show that fecal microbiota transplantation from healthy donors can upregulate inhibitory checkpoints and delay diabetes in NOD mice. Clinical trials testing specific probiotics or prebiotics are underway, though results are preliminary.

Beyond Checkpoints: The Next Wave of Immunometabolic Targets

Checkpoint regulation intersects with cellular metabolism, and recent studies have revealed that metabolic pathways like glycolysis, fatty acid oxidation, and mTOR signaling profoundly influence checkpoint function. For example, metabolically exhausted T cells in the pancreatic islet microenvironment upregulate PD-1 but are unable to execute effective suppression. Agents that modulate the metabolic fitness of T cells—such as metformin, which enhances oxidative phosphorylation—could synergize with checkpoint agonists to restore regulatory capacity. Clinical trials combining metformin with teplizumab or abatacept are being designed.

Collaborative Efforts and Data Sharing

Progress in checkpoint immunotherapy for T1D increasingly depends on large-scale collaborative networks that share biospecimens, clinical data, and trial results. Initiatives like the Immune Tolerance Network (ITN), JDRF-funded consortia, and the NIH’s Accelerating Medicines Partnership in T1D are facilitating multi-site trials and harmonized biomarker analysis. Open-access datasets from these efforts enable machine learning models to identify subphenotypes and predict treatment responses, accelerating the pace of discovery.

Conclusion

Immune checkpoint blockade—or, more precisely, checkpoint agonism—represents a promising, though still nascent, therapeutic strategy for type 1 diabetes. By re-engaging the body’s natural brakes on autoimmunity, these agents have the potential to slow or even halt beta cell destruction, reduce insulin dependence, and prevent disease progression in at-risk individuals. Recent advances in understanding PD-1, CTLA-4, LAG-3, and TIM-3 biology have translated into a pipeline of biologicals, small molecules, and gene therapies that are now entering early-phase clinical trials. However, significant challenges remain: ensuring safety without compromising protective immunity, identifying optimal timing and patient populations, and overcoming individual variability in immune responses. The next decade will likely see a proliferation of combination trials, biomarker-guided strategies, and personalized immunotherapies that leverage checkpoint modulation alongside cellular and metabolic interventions. For patients and families affected by T1D, these developments offer genuine hope that the era of purely symptomatic management may soon give way to therapies that address the root cause of the disease.

“We are at a unique inflection point in T1D research, where immune checkpoint modulation—once exclusively the domain of oncology—is being repurposed to rewrite the rules of autoimmune tolerance.” — Dr. Kevan Herold, Yale School of Medicine

For further reading, see the original trial results for abatacept in T1D (NEJM, 2011), recent mechanistic studies on PD-1 agonists in NOD mice (Diabetes, 2020), and ongoing clinical trials on ClinicalTrials.gov (e.g., NCT04522575). For a comprehensive review of immune checkpoints in autoimmunity, consult Nature Reviews Immunology, 2021.